Skip to Content

Join the 'Eluxadoline' group to help and get support from people like you.

Eluxadoline News

FDA Medwatch Alert: Viberzi (eluxadoline): Drug Safety Communication - Increased Risk of Serious Pancreatitis In Patients Without A Gallbladder

Posted 15 Mar 2017 by Drugs.com

ISSUE: FDA is warning that Viberzi (eluxadoline), a medicine used to treat irritable bowel syndrome with diarrhea (IBS-D), should not be used in patients who do not have a gallbladder. An FDA review found these patients have an increased risk of developing serious pancreatitis that could result in hospitalization or death. Pancreatitis may be caused by spasm of a certain digestive system muscle ...

New IBS Drug Eases Stomach Pain and Diarrhea for Some: Study

Posted 21 Jan 2016 by Drugs.com

WEDNESDAY, Jan. 20, 2016 – A new drug for irritable bowel syndrome with diarrhea seems to reduce symptoms for some patients for at least six months, two clinical trials found. Based on these findings, the drug Viberzi (eluxadoline) was approved recently by the U.S. Food and Drug Administration. In the phase 3 trials, more than 30 percent of patients experienced improvement in their symptoms at ...

Two Drugs Approved for Irritable Bowel

Posted 1 Jun 2015 by Drugs.com

THURSDAY, May 28, 2015 – Two new therapies to treat irritable bowel syndrome accompanied by diarrhea (IBS-D) in adults have been approved by the U.S. Food and Drug Administration. IBS, characterized by loose stools and abdominal discomfort, affects 10 percent to 15 percent of U.S. adults, the FDA said in a news release. The first drug, Viberzi, is taken twice daily with food. It stimulates ...

FDA Approves New Drugs for Irritable Bowel Syndrome

Posted 1 Jun 2015 by Drugs.com

THURSDAY, May 28, 2015 – Two new drugs for adults with irritable bowel syndrome with diarrhea (IBS-D) were approved by the U.S. Food and Drug Administration on Wednesday. "For some people, IBS can be quite disabling, and no one medication works for all patients suffering from this gastrointestinal disorder," Dr. Julie Beitz, director of the Office of Drug Evaluation III in FDA's Center for Drug ...

FDA Approves Two Therapies to Treat Irritable Bowel Syndrome with Diarrhea (IBS-D)

Posted 28 May 2015 by Drugs.com

May 27, 2015 – The U.S. Food and Drug Administration today approved Viberzi (eluxadoline) and Xifaxan (rifaximin), two new treatments, manufactured by two different companies, for irritable bowel syndrome with diarrhea (IBS-D) in adult men and women. According to the National Institutes of Health, patients with irritable bowel syndrome (IBS) experience a number of signs and symptoms, ...

FDA Approves Viberzi (eluxadoline) for Irritable Bowel Syndrome with Diarrhea (IBS-D) in Adults

Posted 27 May 2015 by Drugs.com

DUBLIN, May 27, 2015 /PRNewswire/ – Actavis plc (NYSE: ACT) announced today that Viberzi (eluxadoline) was approved by the Food and Drug Administration (FDA) as a twice-daily, oral treatment for adults suffering from irritable bowel syndrome with diarrhea (IBS-D). Viberzi (eluxadoline) has mixed opioid receptor activity, it is a mu receptor agonist, a delta receptor antagonist, and a kappa ...

Ask a Question

Further Information

Related Condition Support Groups

Irritable Bowel Syndrome

Related Drug Support Groups

Viberzi

Eluxadoline Patient Information at Drugs.com